Table 2.
Efficacy of TNF-α inhibitors in the therapy of psoriatic arthritis (randomized controlled trials)
| Agent | Reference | Trial | Treatment (number of patients) | Results (%) |
|---|---|---|---|---|
| Adalimumab (ADEPT) | Mease et al., 2005,Gladman et al., 2007,Mease et al., 2009 | 24-week RDBPC OLE OLE week 48 OLE week 104 | A 40 mg eow (151) Placebo (162) OLE A (281) | ACR 20 at week 12: 58 ACR 20 at week 12: 14 ACR 20 at week 48: 58.7 ACR 20 at week 104: 57.3 |
| Adalimumab | Genovese et al., 2007 | 12-week RDBPC OLE until week 24 | A 40 mg eow (51) Placebo (49) | ACR 20 at week 12: 39 ACR 20 at week 12: 16 |
| Etanercept | Mease et al., 2000 | 12-week RDBPC | E 25 mg twice weekly (30) Placebo (30) | ACR 20 at week 12: 73 ACR 20 at week 12: 13 |
| Etanercept | Mease et al., 2004 | 24-week RDBPC OLE until week 48 | E 25 mg twice weekly (101) Placebo (104) | ACR 20 at week 12: 59 ACR 20 at week 12: 15 |
| Golimumab GO-REVEAL | Kavanaugh et al., 2009a | 24-week RDBPC | G 50 mg q4wks (146) G 100 mg q4wks (146) Placebo (113) | ACR 20 at week 14: 51 ACR 20 at week 14: 45 ACR 20 at week 14: 9 |
| Infliximab IMPACT | Antoni et al., 2005 | 16-week RDBPC OLE week 50 | Infliximab 5 mg·kg−1 (52) Placebo (52) | ACR 20 at week 16: 65 ACR 20 at week 16: 10 |
| Infliximab IMPACT II | Kavanaugh et al., 2007 | 24-week RDBPC OLE 52 weeks | Infliximab 5 mg·kg−1 (100) Placebo (100) | ACR 20 at week 24: 54 ACR 20 at week 24: 16 |
A, adalimumab; E, etanercept; eow, every other week; G, golimumab; OLE, open level extension; q4wks, every 4 weeks; RDBPC, randomized double-blind placebo controlled trial.